APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tumour Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Tumour Vaccine Market Analysis and Forecast 2026-2032

31 December 2025205 pages

Choose your research edition.

Industry ResearchTumour Vaccine Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Tumour Vaccine Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Tumour Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tumour Vaccine Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Tumour Vaccine Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Tumour Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Tumour Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Tumour Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Tumour Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Tumour Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Tumour Vaccine include Advaxis, Agenus Inc, Avidea Technologies, BioNTech, BrightPath Biotherapeutics, Genocea Biosciences Inc, Gritstone Bio, ISA Pharmaceuticals and Medigene AG, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Tumour Vaccine, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Tumour Vaccine, also provides the revenue of main regions and countries. Of the upcoming market potential for Tumour Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Tumour Vaccine revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Tumour Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Tumour Vaccine revenue, projected growth trends, production technology, application and end-user industry.

Tumour Vaccine Segment by Company

Advaxis

Agenus Inc

Avidea Technologies

BioNTech

BrightPath Biotherapeutics

Genocea Biosciences Inc

Gritstone Bio

ISA Pharmaceuticals

Medigene AG

Moderna

Nouscom

Novogene

OSE Immunotherapeutics

Roche Holding AG

Vaccibody AS

Vaximm AG

ZIOPHARM Oncology

Pfizer

Eli Lilly and Company

Merck & Co Inc

Tumour Vaccine Segment by Type

Personalized Vaccine

Off-the shelf Vaccine

Tumour Vaccine Segment by Application

Gastrointestinal Cancer

Lung Cancer

Melanoma Cancer

Brain Cancer

Others

Tumour Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumour Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tumour Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumour Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Tumour Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Tumour Vaccine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Tumour Vaccine revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Tumour Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Personalized Vaccine Major Player Table 3. Off-the shelf Vaccine Major Player Table 4. Global Tumour Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Gastrointestinal Cancer Major Player Table 6. Lung Cancer Major Player Table 7. Melanoma Cancer Major Player Table 8. Brain Cancer Major Player Table 9. Others Major Player Table 10. Tumour Vaccine Industry Trends Table 11. Tumour Vaccine Industry Drivers Table 12. Tumour Vaccine Industry Opportunities and Challenges Table 13. Tumour Vaccine Industry Restraints Table 14. Global Tumour Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Tumour Vaccine Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Tumour Vaccine Market Share by Region (2021-2026) Table 17. Global Tumour Vaccine Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Tumour Vaccine Market Share by Region (2027-2032) Table 19. Global Tumour Vaccine Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Tumour Vaccine Revenue Market Share by Players (2021-2026) Table 21. Global Tumour Vaccine Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Tumour Vaccine Key Players Headquarters & Area Served Table 23. Global Tumour Vaccine Players, Product Type & Application Table 24. Global Tumour Vaccine Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Tumour Vaccine by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Tumour Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Tumour Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Tumour Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Tumour Vaccine Revenue Market Share by Type (2021-2026) Table 31. Global Tumour Vaccine Revenue Market Share by Type (2027-2032) Table 32. Global Tumour Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Tumour Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Tumour Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Tumour Vaccine Revenue Market Share by Application (2021-2026) Table 36. Global Tumour Vaccine Revenue Market Share by Application (2027-2032) Table 37. Advaxis Company Information Table 38. Advaxis Business Overview Table 39. Advaxis Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Advaxis Tumour Vaccine Product Portfolio Table 41. Advaxis Recent Development Table 42. Agenus Inc Company Information Table 43. Agenus Inc Business Overview Table 44. Agenus Inc Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Agenus Inc Tumour Vaccine Product Portfolio Table 46. Agenus Inc Recent Development Table 47. Avidea Technologies Company Information Table 48. Avidea Technologies Business Overview Table 49. Avidea Technologies Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Avidea Technologies Tumour Vaccine Product Portfolio Table 51. Avidea Technologies Recent Development Table 52. BioNTech Company Information Table 53. BioNTech Business Overview Table 54. BioNTech Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. BioNTech Tumour Vaccine Product Portfolio Table 56. BioNTech Recent Development Table 57. BrightPath Biotherapeutics Company Information Table 58. BrightPath Biotherapeutics Business Overview Table 59. BrightPath Biotherapeutics Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. BrightPath Biotherapeutics Tumour Vaccine Product Portfolio Table 61. BrightPath Biotherapeutics Recent Development Table 62. Genocea Biosciences Inc Company Information Table 63. Genocea Biosciences Inc Business Overview Table 64. Genocea Biosciences Inc Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Genocea Biosciences Inc Tumour Vaccine Product Portfolio Table 66. Genocea Biosciences Inc Recent Development Table 67. Gritstone Bio Company Information Table 68. Gritstone Bio Business Overview Table 69. Gritstone Bio Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Gritstone Bio Tumour Vaccine Product Portfolio Table 71. Gritstone Bio Recent Development Table 72. ISA Pharmaceuticals Company Information Table 73. ISA Pharmaceuticals Business Overview Table 74. ISA Pharmaceuticals Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. ISA Pharmaceuticals Tumour Vaccine Product Portfolio Table 76. ISA Pharmaceuticals Recent Development Table 77. Medigene AG Company Information Table 78. Medigene AG Business Overview Table 79. Medigene AG Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Medigene AG Tumour Vaccine Product Portfolio Table 81. Medigene AG Recent Development Table 82. Moderna Company Information Table 83. Moderna Business Overview Table 84. Moderna Tumour Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Moderna Tumour Vaccine Product Portfolio Table 86. Moderna Recent Development Table 87. Nouscom Company Information Table 88. Nouscom Business Overview Table 89. Nouscom Tumour Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Nouscom Tumour Vaccine Product Portfolio Table 91. Nouscom Recent Development Table 92. Novogene Company Information Table 93. Novogene Business Overview Table 94. Novogene Tumour Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Novogene Tumour Vaccine Product Portfolio Table 96. Novogene Recent Development Table 97. OSE Immunotherapeutics Company Information Table 98. OSE Immunotherapeutics Business Overview Table 99. OSE Immunotherapeutics Tumour Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. OSE Immunotherapeutics Tumour Vaccine Product Portfolio Table 101. OSE Immunotherapeutics Recent Development Table 102. Roche Holding AG Company Information Table 103. Roche Holding AG Business Overview Table 104. Roche Holding AG Tumour Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Roche Holding AG Tumour Vaccine Product Portfolio Table 106. Roche Holding AG Recent Development Table 107. Vaccibody AS Company Information Table 108. Vaccibody AS Business Overview Table 109. Vaccibody AS Tumour Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Vaccibody AS Tumour Vaccine Product Portfolio Table 111. Vaccibody AS Recent Development Table 112. Vaximm AG Company Information Table 113. Vaximm AG Business Overview Table 114. Vaximm AG Tumour Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Vaximm AG Tumour Vaccine Product Portfolio Table 116. Vaximm AG Recent Development Table 117. ZIOPHARM Oncology Company Information Table 118. ZIOPHARM Oncology Business Overview Table 119. ZIOPHARM Oncology Tumour Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. ZIOPHARM Oncology Tumour Vaccine Product Portfolio Table 121. ZIOPHARM Oncology Recent Development Table 122. Pfizer Company Information Table 123. Pfizer Business Overview Table 124. Pfizer Tumour Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Pfizer Tumour Vaccine Product Portfolio Table 126. Pfizer Recent Development Table 127. Eli Lilly and Company Company Information Table 128. Eli Lilly and Company Business Overview Table 129. Eli Lilly and Company Tumour Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Eli Lilly and Company Tumour Vaccine Product Portfolio Table 131. Eli Lilly and Company Recent Development Table 132. Merck & Co Inc Company Information Table 133. Merck & Co Inc Business Overview Table 134. Merck & Co Inc Tumour Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Merck & Co Inc Tumour Vaccine Product Portfolio Table 136. Merck & Co Inc Recent Development Table 137. North America Tumour Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 138. North America Tumour Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 139. North America Tumour Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 140. North America Tumour Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 141. North America Tumour Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. North America Tumour Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 143. North America Tumour Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 144. Europe Tumour Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 145. Europe Tumour Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 146. Europe Tumour Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 147. Europe Tumour Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 148. Europe Tumour Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. Europe Tumour Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 150. Europe Tumour Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 151. China Tumour Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 152. China Tumour Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 153. China Tumour Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 154. China Tumour Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 155. Asia Tumour Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 156. Asia Tumour Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 157. Asia Tumour Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 158. Asia Tumour Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 159. Asia Tumour Vaccine Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 160. Asia Tumour Vaccine Revenue by Region (US$ Million) & (2021-2026) Table 161. Asia Tumour Vaccine Revenue by Region (US$ Million) & (2027-2032) Table 162. SAMEA Tumour Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 163. SAMEA Tumour Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 164. SAMEA Tumour Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 165. SAMEA Tumour Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 166. SAMEA Tumour Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 167. SAMEA Tumour Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 168. SAMEA Tumour Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Tumour Vaccine Image Figure 2. Global Tumour Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tumour Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Personalized Vaccine Image Figure 5. Off-the shelf Vaccine Image Figure 6. Global Tumour Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Tumour Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Gastrointestinal Cancer Image Figure 9. Lung Cancer Image Figure 10. Melanoma Cancer Image Figure 11. Brain Cancer Image Figure 12. Others Image Figure 13. Global Tumour Vaccine Market Size (US$ Million) & (2021-2032) Figure 14. Global Tumour Vaccine Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Tumour Vaccine Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Tumour Vaccine Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Tumour Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Tumour Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Tumour Vaccine Revenue Market Share by Type (2021-2032) Figure 21. Global Tumour Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Tumour Vaccine Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Tumour Vaccine Revenue Market Share by Application (2021-2032) Figure 24. North America Tumour Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Tumour Vaccine Revenue Share by Type (2021-2032) Figure 26. North America Tumour Vaccine Revenue Share by Application (2021-2032) Figure 27. North America Tumour Vaccine Revenue Share by Country (2021-2032) Figure 28. United States Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Tumour Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Tumour Vaccine Revenue Share by Type (2021-2032) Figure 33. Europe Tumour Vaccine Revenue Share by Application (2021-2032) Figure 34. Europe Tumour Vaccine Revenue Share by Country (2021-2032) Figure 35. Germany Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Tumour Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Tumour Vaccine Revenue Share by Type (2021-2032) Figure 45. China Tumour Vaccine Revenue Share by Application (2021-2032) Figure 46. Asia Tumour Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Tumour Vaccine Revenue Share by Type (2021-2032) Figure 48. Asia Tumour Vaccine Revenue Share by Application (2021-2032) Figure 49. Asia Tumour Vaccine Revenue Share by Region (2021-2032) Figure 50. Japan Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Tumour Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Tumour Vaccine Revenue Share by Type (2021-2032) Figure 58. SAMEA Tumour Vaccine Revenue Share by Application (2021-2032) Figure 59. SAMEA Tumour Vaccine Revenue Share by Country (2021-2032) Figure 60. Brazil Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Tumour Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Personalized Vaccine
  • Off-the shelf Vaccine
Applications
  • Gastrointestinal Cancer
  • Lung Cancer
  • Melanoma Cancer
  • Brain Cancer
  • Others
Companies covered
  • Advaxis
  • Agenus Inc
  • Avidea Technologies
  • BioNTech
  • BrightPath Biotherapeutics
  • Genocea Biosciences Inc
  • Gritstone Bio
  • ISA Pharmaceuticals
  • Medigene AG
  • Moderna
  • Nouscom
  • Novogene
  • OSE Immunotherapeutics
  • Roche Holding AG
  • Vaccibody AS
  • Vaximm AG
  • ZIOPHARM Oncology
  • Pfizer
  • Eli Lilly and Company
  • Merck & Co Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Tumour Vaccine Market by Type
  3. 1.2.1 Global Tumour Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Personalized Vaccine
  5. 1.2.3 Off-the shelf Vaccine
  6. 1.3 Tumour Vaccine Market by Application
  7. 1.3.1 Global Tumour Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Gastrointestinal Cancer
  9. 1.3.3 Lung Cancer
  10. 1.3.4 Melanoma Cancer
  11. 1.3.5 Brain Cancer
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Tumour Vaccine Market Dynamics
  1. 2.1 Tumour Vaccine Industry Trends
  2. 2.2 Tumour Vaccine Industry Drivers
  3. 2.3 Tumour Vaccine Industry Opportunities and Challenges
  4. 2.4 Tumour Vaccine Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Tumour Vaccine Market Perspective (2021-2032)
  2. 3.2 Global Tumour Vaccine Growth Trends by Region
  3. 3.2.1 Global Tumour Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Tumour Vaccine Market Size by Region (2021-2026)
  5. 3.2.3 Global Tumour Vaccine Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Tumour Vaccine Revenue by Players
  2. 4.1.1 Global Tumour Vaccine Revenue by Players (2021-2026)
  3. 4.1.2 Global Tumour Vaccine Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Tumour Vaccine Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Tumour Vaccine Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Tumour Vaccine Key Players Headquarters & Area Served
  7. 4.4 Global Tumour Vaccine Players, Product Type & Application
  8. 4.5 Global Tumour Vaccine Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Tumour Vaccine Market CR5 and HHI
  11. 4.6.3 2025 Tumour Vaccine Tier 1, Tier 2, and Tier 3
5 Tumour Vaccine Market Size by Type
  1. 5.1 Global Tumour Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Tumour Vaccine Revenue by Type (2021-2032)
  3. 5.3 Global Tumour Vaccine Revenue Market Share by Type (2021-2032)
6 Tumour Vaccine Market Size by Application
  1. 6.1 Global Tumour Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Tumour Vaccine Revenue by Application (2021-2032)
  3. 6.3 Global Tumour Vaccine Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Advaxis
  2. 7.1.1 Advaxis Company Information
  3. 7.1.2 Advaxis Business Overview
  4. 7.1.3 Advaxis Tumour Vaccine Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Advaxis Tumour Vaccine Product Portfolio
  6. 7.1.5 Advaxis Recent Developments
  7. 7.2 Agenus Inc
  8. 7.2.1 Agenus Inc Company Information
  9. 7.2.2 Agenus Inc Business Overview
  10. 7.2.3 Agenus Inc Tumour Vaccine Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Agenus Inc Tumour Vaccine Product Portfolio
  12. 7.2.5 Agenus Inc Recent Developments
  13. 7.3 Avidea Technologies
  14. 7.3.1 Avidea Technologies Company Information
  15. 7.3.2 Avidea Technologies Business Overview
  16. 7.3.3 Avidea Technologies Tumour Vaccine Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Avidea Technologies Tumour Vaccine Product Portfolio
  18. 7.3.5 Avidea Technologies Recent Developments
  19. 7.4 BioNTech
  20. 7.4.1 BioNTech Company Information
  21. 7.4.2 BioNTech Business Overview
  22. 7.4.3 BioNTech Tumour Vaccine Revenue and Gross Margin (2021-2026)
  23. 7.4.4 BioNTech Tumour Vaccine Product Portfolio
  24. 7.4.5 BioNTech Recent Developments
  25. 7.5 BrightPath Biotherapeutics
  26. 7.5.1 BrightPath Biotherapeutics Company Information
  27. 7.5.2 BrightPath Biotherapeutics Business Overview
  28. 7.5.3 BrightPath Biotherapeutics Tumour Vaccine Revenue and Gross Margin (2021-2026)
  29. 7.5.4 BrightPath Biotherapeutics Tumour Vaccine Product Portfolio
  30. 7.5.5 BrightPath Biotherapeutics Recent Developments
  31. 7.6 Genocea Biosciences Inc
  32. 7.6.1 Genocea Biosciences Inc Company Information
  33. 7.6.2 Genocea Biosciences Inc Business Overview
  34. 7.6.3 Genocea Biosciences Inc Tumour Vaccine Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Genocea Biosciences Inc Tumour Vaccine Product Portfolio
  36. 7.6.5 Genocea Biosciences Inc Recent Developments
  37. 7.7 Gritstone Bio
  38. 7.7.1 Gritstone Bio Company Information
  39. 7.7.2 Gritstone Bio Business Overview
  40. 7.7.3 Gritstone Bio Tumour Vaccine Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Gritstone Bio Tumour Vaccine Product Portfolio
  42. 7.7.5 Gritstone Bio Recent Developments
  43. 7.8 ISA Pharmaceuticals
  44. 7.8.1 ISA Pharmaceuticals Company Information
  45. 7.8.2 ISA Pharmaceuticals Business Overview
  46. 7.8.3 ISA Pharmaceuticals Tumour Vaccine Revenue and Gross Margin (2021-2026)
  47. 7.8.4 ISA Pharmaceuticals Tumour Vaccine Product Portfolio
  48. 7.8.5 ISA Pharmaceuticals Recent Developments
  49. 7.9 Medigene AG
  50. 7.9.1 Medigene AG Company Information
  51. 7.9.2 Medigene AG Business Overview
  52. 7.9.3 Medigene AG Tumour Vaccine Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Medigene AG Tumour Vaccine Product Portfolio
  54. 7.9.5 Medigene AG Recent Developments
  55. 7.10 Moderna
  56. 7.10.1 Moderna Company Information
  57. 7.10.2 Moderna Business Overview
  58. 7.10.3 Moderna Tumour Vaccine Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Moderna Tumour Vaccine Product Portfolio
  60. 7.10.5 Moderna Recent Developments
  61. 7.11 Nouscom
  62. 7.11.1 Nouscom Company Information
  63. 7.11.2 Nouscom Business Overview
  64. 7.11.3 Nouscom Tumour Vaccine Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Nouscom Tumour Vaccine Product Portfolio
  66. 7.11.5 Nouscom Recent Developments
  67. 7.12 Novogene
  68. 7.12.1 Novogene Company Information
  69. 7.12.2 Novogene Business Overview
  70. 7.12.3 Novogene Tumour Vaccine Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Novogene Tumour Vaccine Product Portfolio
  72. 7.12.5 Novogene Recent Developments
  73. 7.13 OSE Immunotherapeutics
  74. 7.13.1 OSE Immunotherapeutics Company Information
  75. 7.13.2 OSE Immunotherapeutics Business Overview
  76. 7.13.3 OSE Immunotherapeutics Tumour Vaccine Revenue and Gross Margin (2021-2026)
  77. 7.13.4 OSE Immunotherapeutics Tumour Vaccine Product Portfolio
  78. 7.13.5 OSE Immunotherapeutics Recent Developments
  79. 7.14 Roche Holding AG
  80. 7.14.1 Roche Holding AG Company Information
  81. 7.14.2 Roche Holding AG Business Overview
  82. 7.14.3 Roche Holding AG Tumour Vaccine Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Roche Holding AG Tumour Vaccine Product Portfolio
  84. 7.14.5 Roche Holding AG Recent Developments
  85. 7.15 Vaccibody AS
  86. 7.15.1 Vaccibody AS Company Information
  87. 7.15.2 Vaccibody AS Business Overview
  88. 7.15.3 Vaccibody AS Tumour Vaccine Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Vaccibody AS Tumour Vaccine Product Portfolio
  90. 7.15.5 Vaccibody AS Recent Developments
  91. 7.16 Vaximm AG
  92. 7.16.1 Vaximm AG Company Information
  93. 7.16.2 Vaximm AG Business Overview
  94. 7.16.3 Vaximm AG Tumour Vaccine Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Vaximm AG Tumour Vaccine Product Portfolio
  96. 7.16.5 Vaximm AG Recent Developments
  97. 7.17 ZIOPHARM Oncology
  98. 7.17.1 ZIOPHARM Oncology Company Information
  99. 7.17.2 ZIOPHARM Oncology Business Overview
  100. 7.17.3 ZIOPHARM Oncology Tumour Vaccine Revenue and Gross Margin (2021-2026)
  101. 7.17.4 ZIOPHARM Oncology Tumour Vaccine Product Portfolio
  102. 7.17.5 ZIOPHARM Oncology Recent Developments
  103. 7.18 Pfizer
  104. 7.18.1 Pfizer Company Information
  105. 7.18.2 Pfizer Business Overview
  106. 7.18.3 Pfizer Tumour Vaccine Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Pfizer Tumour Vaccine Product Portfolio
  108. 7.18.5 Pfizer Recent Developments
  109. 7.19 Eli Lilly and Company
  110. 7.19.1 Eli Lilly and Company Company Information
  111. 7.19.2 Eli Lilly and Company Business Overview
  112. 7.19.3 Eli Lilly and Company Tumour Vaccine Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Eli Lilly and Company Tumour Vaccine Product Portfolio
  114. 7.19.5 Eli Lilly and Company Recent Developments
  115. 7.20 Merck & Co Inc
  116. 7.20.1 Merck & Co Inc Company Information
  117. 7.20.2 Merck & Co Inc Business Overview
  118. 7.20.3 Merck & Co Inc Tumour Vaccine Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Merck & Co Inc Tumour Vaccine Product Portfolio
  120. 7.20.5 Merck & Co Inc Recent Developments
8 North America
  1. 8.1 North America Tumour Vaccine Revenue (2021-2032)
  2. 8.2 North America Tumour Vaccine Revenue by Type (2021-2032)
  3. 8.2.1 North America Tumour Vaccine Revenue by Type (2021-2026)
  4. 8.2.2 North America Tumour Vaccine Revenue by Type (2027-2032)
  5. 8.3 North America Tumour Vaccine Revenue Share by Type (2021-2032)
  6. 8.4 North America Tumour Vaccine Revenue by Application (2021-2032)
  7. 8.4.1 North America Tumour Vaccine Revenue by Application (2021-2026)
  8. 8.4.2 North America Tumour Vaccine Revenue by Application (2027-2032)
  9. 8.5 North America Tumour Vaccine Revenue Share by Application (2021-2032)
  10. 8.6 North America Tumour Vaccine Revenue by Country
  11. 8.6.1 North America Tumour Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Tumour Vaccine Revenue by Country (2021-2026)
  13. 8.6.3 North America Tumour Vaccine Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Tumour Vaccine Revenue (2021-2032)
  2. 9.2 Europe Tumour Vaccine Revenue by Type (2021-2032)
  3. 9.2.1 Europe Tumour Vaccine Revenue by Type (2021-2026)
  4. 9.2.2 Europe Tumour Vaccine Revenue by Type (2027-2032)
  5. 9.3 Europe Tumour Vaccine Revenue Share by Type (2021-2032)
  6. 9.4 Europe Tumour Vaccine Revenue by Application (2021-2032)
  7. 9.4.1 Europe Tumour Vaccine Revenue by Application (2021-2026)
  8. 9.4.2 Europe Tumour Vaccine Revenue by Application (2027-2032)
  9. 9.5 Europe Tumour Vaccine Revenue Share by Application (2021-2032)
  10. 9.6 Europe Tumour Vaccine Revenue by Country
  11. 9.6.1 Europe Tumour Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Tumour Vaccine Revenue by Country (2021-2026)
  13. 9.6.3 Europe Tumour Vaccine Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Tumour Vaccine Revenue (2021-2032)
  2. 10.2 China Tumour Vaccine Revenue by Type (2021-2032)
  3. 10.2.1 China Tumour Vaccine Revenue by Type (2021-2026)
  4. 10.2.2 China Tumour Vaccine Revenue by Type (2027-2032)
  5. 10.3 China Tumour Vaccine Revenue Share by Type (2021-2032)
  6. 10.4 China Tumour Vaccine Revenue by Application (2021-2032)
  7. 10.4.1 China Tumour Vaccine Revenue by Application (2021-2026)
  8. 10.4.2 China Tumour Vaccine Revenue by Application (2027-2032)
  9. 10.5 China Tumour Vaccine Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Tumour Vaccine Revenue (2021-2032)
  2. 11.2 Asia Tumour Vaccine Revenue by Type (2021-2032)
  3. 11.2.1 Asia Tumour Vaccine Revenue by Type (2021-2026)
  4. 11.2.2 Asia Tumour Vaccine Revenue by Type (2027-2032)
  5. 11.3 Asia Tumour Vaccine Revenue Share by Type (2021-2032)
  6. 11.4 Asia Tumour Vaccine Revenue by Application (2021-2032)
  7. 11.4.1 Asia Tumour Vaccine Revenue by Application (2021-2026)
  8. 11.4.2 Asia Tumour Vaccine Revenue by Application (2027-2032)
  9. 11.5 Asia Tumour Vaccine Revenue Share by Application (2021-2032)
  10. 11.6 Asia Tumour Vaccine Revenue by Country
  11. 11.6.1 Asia Tumour Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Tumour Vaccine Revenue by Country (2021-2026)
  13. 11.6.3 Asia Tumour Vaccine Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Tumour Vaccine Revenue (2021-2032)
  2. 12.2 SAMEA Tumour Vaccine Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Tumour Vaccine Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Tumour Vaccine Revenue by Type (2027-2032)
  5. 12.3 SAMEA Tumour Vaccine Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Tumour Vaccine Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Tumour Vaccine Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Tumour Vaccine Revenue by Application (2027-2032)
  9. 12.5 SAMEA Tumour Vaccine Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Tumour Vaccine Revenue by Country
  11. 12.6.1 SAMEA Tumour Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Tumour Vaccine Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Tumour Vaccine Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst